Charles River Laboratories International, Inc.

What they do

The company operates over 120 sites in over 20 countries and serves major pharmaceutical, biotechnology, and other life science clients. Its three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. RMS includes production and sale of small/large research models, insourcing solutions, genetically engineered models, and diagnostics. DSA provides non-clinical discovery, safety testing, and bioanalytical services. Manufacturing includes microbial detection and biologics testing (CDMO divested in May 2026).

Revenue drivers

• Research Models and Services (RMS) — Generates revenue from commercial production/sale of research models, colony management via Insourcing Solutions, contract breeding (GEMS), and animal diagnostics. This segment includes Cell Solutions, which was divested in May 2026.
• Discovery and Safety Assessment (DSA) — Provides in vitro, in vivo, and in silico studies for drug discovery and regulatory safety testing, plus bioanalytical and consulting services. Backlog improved to $2.0 billion as of June 2026.
• Manufacturing Solutions — Includes Microbial Solutions (lot-release testing, microbial detection) and Biologics Testing Solutions. The CDMO business within this segment was divested in May 2026.

Recent performance

In Q2 2026 (ended June 27, 2026), revenue was $1.00 billion, down 2.7% year-over-year, but organic revenue grew 0.1%. GAAP net loss was $(1.5) million ($(0.03) per diluted share) versus net income of $52.3 million a year ago, primarily due to a $63.7 million loss from divesting CDMO and Cell Solutions. Non-GAAP EPS was $3.02, down 3.2% from $3.12, and non-GAAP operating margin decreased to 20.5% from 22.1% due to higher direct costs and corporate costs.

Strategy

Management is executing a 'Pathway to Purpose' strategy focusing on modernizing the company, strengthening the drug development portfolio around regulated testing, and enhancing growth. In May 2026, the company divested certain European Discovery Services, CDMO, and Cell Solutions businesses to refine its portfolio. Cost savings initiatives targeting approximately $300 million in cumulative annualized savings are underway through process improvements, procurement synergies, and a global business services model. The company also joined Eli Lilly's TuneLab AI platform and introduced an AI-enabled digital pathology solution to drive modernization.

Risks

• Contract risks — The company bears financial risk for contracts that may be terminated, reduced in scope, underpriced, or subject to cost overruns and delays.
• Cybersecurity threats — Past unauthorized access into information systems could recur, potentially disrupting operations and exposing sensitive data.
• AI-related uncertainties — The development, deployment, and use of artificial intelligence present new risks and challenges that could adversely affect the company's business and reputation.
• Execution of strategic actions — Failure to successfully select and integrate acquisitions, manage site closures and divestitures (including the recent CDMO and Cell Solutions sales) could harm business performance.

Outlook

Management noted a cautious but improving spending environment, especially in the DSA segment, which saw the highest net book-to-bill in nearly four years in Q2 2026. The company raised its 2026 guidance for revenue (organic growth by 150 basis points) and non-GAAP EPS (by $0.25 at the midpoint), driven by improving DSA demand and better-than-expected Manufacturing performance. DSA backlog increased to $2.0 billion from $1.9 billion at year-end 2025.